Sanofi CFO: Offering New Treatments for Diabetes

The video features an interview with Jerome Condamine, CFO of a pharmaceutical company, discussing the impact of Trump's comments on drug pricing and the company's strategy to address challenges in the diabetes market. The company is focusing on innovation with new treatments like Toujeo and Dupixent, while being cautious about mergers and acquisitions. The discussion highlights the competitive landscape and the need for responsible pricing strategies.

How does the company plan to address the competitive pressures in the diabetes treatment market?

What are the company's expectations regarding the launch of Dupixent?

What factors does the company consider important when evaluating potential acquisitions?